Literature DB >> 11465946

Pemphigus vulgaris: the role of IL-1 and IL-1 receptor antagonist in pathogenesis and effects of intravenous immunoglobulin on their production.

K C Bhol1, A Desai, S Kumari, J E Colon, A R Ahmed.   

Abstract

Intravenous immunoglobulin (IVIG) is increasingly being used for the treatment of autoimmune diseases. In the present report, the role of IVIG on in vivo and in vitro production of IL-1 and IL-1 receptor antagonist (Ra) was studied in patients with pemphigus vulgaris (PV). Serum samples from 20 untreated patients with active PV prior to initiation of systemic therapy, 20 patients receiving IVIG treatment, 20 patients in clinical remission after conventional therapy, and 20 normal human controls were studied to determine the serum levels of IL-1alpha, IL-1beta, and IL-1Ra. The in vitro production of these cytokines was measured in the culture supernatant of peripheral blood mononuclear cells (PBMC) from 10 PV patients immediately before and after IVIG therapy and from age and sex-matched 10 healthy donors simultaneously. Elevated levels of IL-1alpha and IL-1beta were detected (i) in the serum of untreated PV patients with active disease prior to systemic therapy and (ii) before IVIG infusions in patients receiving IVIG therapy. These increased levels are statistically significant when compared to the levels in healthy controls (P < 0.01). A marked reduction of IL-1alpha and IL-1beta was detected (i) in the serum of patients in prolonged clinical remission and (ii) immediately after IVIG infusion in those patients on IVIG therapy. Increased level of IL-1Ra was detected in PV patients in prolonged clinical remission and after IVIG infusion in those receiving IVIG therapy. These differences were statistically significant when compared to the levels in normal controls and to the levels in the sera of patients with active disease (P < 0.01) or just before the beginning of IVIG infusion (P < 0.01). Similar differences in the levels of IL-1alpha, IL-1beta, and IL-1Ra were found in the culture supernatant of PBMC isolated from the PV patients pre and post IVIG therapy. These observations suggests that, compared to normal controls, patients with active PV have reversed levels of IL-1alpha, IL-1beta, and IL-1Ra. IVIG therapy may down-regulate production of IL-1alpha and IL-1beta and enhance production of IL-1Ra, in vivo and in vitro. This might be one of the important mechanisms by which IVIG produces its early therapeutic effects in pemphigus vulgaris. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11465946     DOI: 10.1006/clim.2001.5061

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  15 in total

Review 1.  Immunomodulatory action of intravenous immunoglobulin.

Authors:  W A C Sewell; S Jolles
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

2.  Novel mechanisms of target cell death and survival and of therapeutic action of IVIg in Pemphigus.

Authors:  Juan Arredondo; Alexander I Chernyavsky; Ali Karaouni; Sergei A Grando
Journal:  Am J Pathol       Date:  2005-12       Impact factor: 4.307

Review 3.  Intravenous immunoglobulin: an update on the clinical use and mechanisms of action.

Authors:  Vir-Singh Negi; Sriramulu Elluru; Sophie Sibéril; Stéphanie Graff-Dubois; Luc Mouthon; Michel D Kazatchkine; Sébastien Lacroix-Desmazes; Jagadeesh Bayry; Srini V Kaveri
Journal:  J Clin Immunol       Date:  2007-03-11       Impact factor: 8.317

4.  Possible role of natural killer cells in pemphigus vulgaris - preliminary observations.

Authors:  J N H Stern; D B Keskin; N Barteneva; J Zuniga; E J Yunis; A R Ahmed
Journal:  Clin Exp Immunol       Date:  2008-03-28       Impact factor: 4.330

Review 5.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

6.  Elevated expression of NLRP1 and IPAF are related to oral pemphigus vulgaris pathogenesis.

Authors:  Reza Mahvelati Shamsabadi; Soroush Basafa; Reza Yarahmadi; Samaneh Goorani; Masood Khani; Maryam Kamarehei; Amir Hossein Kiani
Journal:  Inflammation       Date:  2015-02       Impact factor: 4.092

7.  The efficiency of intraperitoneal high-dose immunoglobulin in experimental nephrotic syndrome.

Authors:  Seyhan Erisir; Halide Akbas; Mustafa Koyun; Sema Akman
Journal:  Pediatr Nephrol       Date:  2005-10-27       Impact factor: 3.714

8.  Recurrent fever syndromes in patients after recovery from Kawasaki syndrome.

Authors:  Lori Broderick; Adriana H Tremoulet; Jane C Burns; John F Bastian; Hal M Hoffman
Journal:  Pediatrics       Date:  2011-01-10       Impact factor: 7.124

9.  Antimitochondrial autoantibodies in pemphigus vulgaris: a missing link in disease pathophysiology.

Authors:  Steve Marchenko; Alexander I Chernyavsky; Juan Arredondo; Vivian Gindi; Sergei A Grando
Journal:  J Biol Chem       Date:  2009-12-10       Impact factor: 5.157

10.  High levels of interleukin-1 in patients with endemic pemphigus foliaceus.

Authors:  Denise Bertulucci Rocha-Rodrigues; Giovana Paschoini; Sanivia Aparecida Lima Pereira; Marlene Antonia dos Reis; Vicente de Paula Antunes Teixeira; Virmondes Rodrigues Júnior
Journal:  Clin Diagn Lab Immunol       Date:  2003-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.